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OA (0.66 ≥ r ≥ 0.40) as measured by KL scores. The MRI-Atlas measure-
ments also correlated with the medial JSN OARSI scores and with the JSW
(r ≤ 0.48). Even with this small sample size the results are encouraging, and
indicate the potential of atlas-based measurements for diagnosing, staging
and evaluating progression of OA.
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FOUR CLEAVAGE SITES INVOLVING OPTICIN AND METALLOPROTEINASES.
NEW FRAGMENTS AS BIOMARKERS IN OA?
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Purpose: Opticin is a glycoprotein belonging to small leucine rich
proteoglicans (SLRPs) family. These proteoglicans are part of the cartilage
extracellular matrix and are associated with the collagen ﬁbrils, regulating
ﬁbril morphology, spacing, and organization. In a previous work we studied
the opticin degradation by different MMPs and ADAMTS involved in OA
pathology, and we observed that digestion patterns were different not only
between the several proteases but also between the proteoglicans extract
obtained from OA cartilage and normal one. This work showed us the be-
havior of this glycoprotein in an environment close to the one found in vivo
but it was not suitable to perform sequencing of the fragments generated.
In order to complete the knowledge of these digestions and to identify
the fragments generated, we decided to study the digestion with human
recombinant opticin. The digestions were performed with the proteases
deﬁned to be the mainly responsible for the development of the OA.
Methods: Recombinant human opticin c-terminal tagged with MYC/DDK
was digested with MMP 1, -2, -3, -7, -8, -9, 13 and ADAMTS-4, -5, at several
incubation times, in a range between 15 minutes and 24 hours. The prote-
olytic activities were analyzed by western blot using both anti-opticin and
anti-MYC antibody. In the case of the opticin digestion with MMP-2 and
MMP-7, they were blot and subsequently transferred to a PVDF membrane.
Finally, the fragments were isolated to perform Edman sequencing.
Results: The metalloproteinases generated different opticin digestion pat-
terns, and we can join up the fragments into four different sizes: 28, 30, 32
and 37 KDa. Each digestion presents at least 2 of these fragments although
with different intensity, depending on the incubation time. These show us
that the digestions are performed in a stepped way and not amioacid by
aminoacid. A previous work has studied the digestion of bovine opticin
by human MMP-13, and described a fragment of 24 kDa generated by the
cleavage between Leu116 and Leu117. If we take into account that the size
of the tag of the human opticin is 3’8 KDa, we can hypothesize that the
fragment of 28 KDa and the 24KDa fragment previously described are the
same. Now we have described three more cleavage sites in opticin, and the
fact that these sites seem to be common for different metalloproteinases.
To study more in detail these fragments, we decided to focus in the study
of the opticin digestion by MMP-2 and MMP-7 for two reasons: on one
hand, they are the ones that digest faster the opticin so they could have
more implication in the degradation of these proteoglycans; and on the
other hand each one produces two representative of the fragments (MMP-2
generates fragments of 32 and 30 KDa and MMP-7 of 37 and 28 KDa). The
generation of these fragments will allow us to sequence the three new
cleavages sites, as well as to conﬁrm the one previously described.
The study of the opticin digestion was performed with two different
antibodies (anti-opticin and anti-MYC). Both antibodies detect the full
opticin, and its digestion can be followed till almost the disappearance of
the band, but only with the anti-MYC antibody the fragments could be
detected. This shows us that, although the opticin antibody is a polyclonal
one, non isoform detects the fragments obtained with the digestion. In a
previous work the digestions were performed with a proteoglican extract
and few fragments could be detected. This study indicated us that the
lack of digestion fragments could be due to lack on the detection and not
because they are not generated.
Conclusions: The digestions of opticin by several proteases yield four
different fragments. Three of them are new cleavages sites for opticin, and
the fourth seems to agree to a one already described. With these data we
try to give a clue of the consensus cleaving sites of metalloproteinases as
well as describing potentials biomarkers for OA. Furthermore, we ﬁnd out
that almost none of the fragments of digestion could be detect with an
anti-opticin polyclonal antibody. This result should be take into account in
future works studying protein degradation.
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A NOVEL BIOCHEMICAL MARKER OF MMP-DERIVED TYPE II COLLAGEN
DEGRADATION FOR JOINT DEGENERATIVE DISEASES, CIIM, IS
CORRELATED TO CARTILAGE VOLUME
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Purpose: Joint degenerative diseases are characterized as progressive loss
of articular cartilage. Cartilage matrix molecules are broken down by
proteases, such as metalloproteinases (MMPs), in this process and protein
fragments are released to the circulation. The level of these fragments can
be measured and used as biomarkers for disease stages or progression.
Type II collagen is the primary cartilage matrix protein and different
MMP-generated fragments have been identiﬁed in body ﬂuids. We target
one of such fragment in the development of a urine biomarker assay.
Methods: Human type II collagen was cleaved with MMP9 in vitro and
analyzed on mass spectrometry. A neoepitope was identiﬁed by Mascot
database search. Monoclonal antibodies were raised against the neoepitope
and a competitive EIA assay was developed: the CIIM assay. The validated
assay was used to measure the level of the type II fragment in urine of
a normal population. Cartilage volume of the knee was measured in 130
individuals by MRI.
Results: The developed immune-assay of CIIM showed good technical
performance and the release of the fragment could be completely inhibited
by MMP inhibitor GM6001, but not by cysteine protease inhibitor E64.
Furthermore the neoepitope could be immune-localized to OA pathological
features in cartilage retrieved from OA patients. A high level of CIIM
was measured in synovial ﬂuid and as well as in urine of individuals
from the MR cohort. The urinary level was signiﬁcantly higher in older
women compared to younger women. Furthermore, low cartilage volume,
measured by MRI, was correlated to high urinary levels of CIIM (p<0.05).
Conclusions: We developed and validated a novel biomarker assay for
MMP-derived type II collagen degradation - CIIM. We have within this
study showed that CIIM was indeed derived from MMP activity and that it
was generated at OA relevant sites in in situ OA cartilage samples. We also
showed that the markers was related to cartilage volume in knees.
130
LARGE-SCALE AND BROAD-SPECTRUM BIOCHEMICAL MARKER ANALYSIS:
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Purpose: Osteoarthritis (OA) is currently regarded as a complex joint
disease; multiple articular and peri-articular structures being involved,
probably in a variable sequence and dominance between individuals.
However, current literature on biochemical OA markers mainly concerns
small-scale and small-spectrum studies and is thereby discordant with this
view. Instead, large-scale and broad-spectrum biochemical marker assess-
ment is preferable. Large-scale assessment might be regarded unfeasible
because of complex logistics, high ﬁnancial burden, and the increased
chance of inducing technical variability. This publication analyzes the chal-
lenges and choices of such a large-scale and broad-spectrum biochemical
marker assessment.
Methods: Eleven biochemical markers were assessed in urine and serum
samples of 1002 participants (Cohort Hip and Cohort Knee; CHECK)
by means of ELISA and RIA in a regular laboratory and commercially-
independent setting. The spectrum of biochemical markers consisted of
markers for cartilage, bone and synovial tissue metabolism and/or cellular
activity. The assessment was necessarily performed by multiple technicians,
in multiple assay plates, and during multiple days. Therefore, speciﬁc at-
tention to minimizing technically-induced variability was vital. In addition
to evaluation of several technical aspects, reliability of single instead of
multiple assessments per sample was evaluated. A standard sample was
repeatedly included in all assay plates throughout the assessment period
to quantify technically-induced variability (3 levels: within plates, within
all plates on a day, in all plates throughout the assessment period) and
evaluate adjustment for between-plate variability.
Results: The additional variation that was introduced by single instead of
